Oncology
✍️ Edit in Keystatic
Guide to Generic Osimertinib in Southeast Asia
A comprehensive clinical reference and overview of third-generation EGFR-TKI Osimertinib formulations across regional manufacturers.
Overview
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor designed to treat non-small cell lung cancer (NSCLC) with EGFR mutations, notably including the T790M resistance mutation.
Clinical Indications
- First-line treatment for patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
- Second-line treatment for patients with EGFR T790M mutation-positive NSCLC progressing after prior EGFR-TKI therapy.
Formulations & Verification
Ensure authentic sourcing from verified pharmaceutical manufacturers compliant with national drug administration standards.
